vs

Side-by-side financial comparison of Esperion Therapeutics, Inc. (ESPR) and Regional Management Corp. (RM). Click either name above to swap in a different company.

Esperion Therapeutics, Inc. is the larger business by last-quarter revenue ($168.4M vs $167.3M, roughly 1.0× Regional Management Corp.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs 9.4%). Over the past eight quarters, Esperion Therapeutics, Inc.'s revenue compounded faster (10.6% CAGR vs 8.2%).

Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.

Millennium Management LLC is an investment management firm with a multistrategy hedge fund offering. It is one of the world's largest alternative asset management firms with $83.4 billion assets under management as of January 2026. The firm operates in America, Europe and Asia. As of 2022, Millennium had posted the fourth highest net gains of any hedge fund since its inception in 1989.

ESPR vs RM — Head-to-Head

Bigger by revenue
ESPR
ESPR
1.0× larger
ESPR
$168.4M
$167.3M
RM
Growing faster (revenue YoY)
ESPR
ESPR
+134.4% gap
ESPR
143.7%
9.4%
RM
Faster 2-yr revenue CAGR
ESPR
ESPR
Annualised
ESPR
10.6%
8.2%
RM

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
ESPR
ESPR
RM
RM
Revenue
$168.4M
$167.3M
Net Profit
$11.4M
Gross Margin
Operating Margin
50.6%
Net Margin
6.8%
Revenue YoY
143.7%
9.4%
Net Profit YoY
62.7%
EPS (diluted)
$0.32
$1.18

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ESPR
ESPR
RM
RM
Q1 26
$167.3M
Q4 25
$168.4M
$169.7M
Q3 25
$87.3M
$165.5M
Q2 25
$82.4M
$157.4M
Q1 25
$65.0M
$153.0M
Q4 24
$69.1M
$154.8M
Q3 24
$51.6M
$146.3M
Q2 24
$73.8M
$143.0M
Net Profit
ESPR
ESPR
RM
RM
Q1 26
$11.4M
Q4 25
$12.9M
Q3 25
$-31.3M
$14.4M
Q2 25
$-12.7M
$10.1M
Q1 25
$-40.5M
$7.0M
Q4 24
$9.9M
Q3 24
$-29.5M
$7.7M
Q2 24
$-61.9M
$8.4M
Operating Margin
ESPR
ESPR
RM
RM
Q1 26
Q4 25
50.6%
9.5%
Q3 25
-11.4%
11.5%
Q2 25
8.6%
8.6%
Q1 25
-34.0%
6.0%
Q4 24
-6.4%
8.2%
Q3 24
-31.0%
6.9%
Q2 24
3.5%
7.8%
Net Margin
ESPR
ESPR
RM
RM
Q1 26
6.8%
Q4 25
7.6%
Q3 25
-35.9%
8.7%
Q2 25
-15.4%
6.4%
Q1 25
-62.2%
4.6%
Q4 24
6.4%
Q3 24
-57.2%
5.2%
Q2 24
-83.9%
5.9%
EPS (diluted)
ESPR
ESPR
RM
RM
Q1 26
$1.18
Q4 25
$0.32
$1.30
Q3 25
$-0.16
$1.42
Q2 25
$-0.06
$1.03
Q1 25
$-0.21
$0.70
Q4 24
$-0.14
$0.96
Q3 24
$-0.15
$0.76
Q2 24
$-0.33
$0.86

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ESPR
ESPR
RM
RM
Cash + ST InvestmentsLiquidity on hand
$167.9M
Total DebtLower is stronger
Stockholders' EquityBook value
$-302.0M
$375.8M
Total Assets
$465.9M
$2.1B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ESPR
ESPR
RM
RM
Q1 26
Q4 25
$167.9M
Q3 25
$92.4M
Q2 25
$86.1M
Q1 25
$114.6M
Q4 24
$144.8M
Q3 24
$144.7M
Q2 24
$189.3M
Total Debt
ESPR
ESPR
RM
RM
Q1 26
Q4 25
$1.6B
Q3 25
$1.6B
Q2 25
$1.5B
Q1 25
$1.5B
Q4 24
$1.5B
Q3 24
$1.4B
Q2 24
$1.4B
Stockholders' Equity
ESPR
ESPR
RM
RM
Q1 26
$375.8M
Q4 25
$-302.0M
$373.1M
Q3 25
$-451.4M
$371.9M
Q2 25
$-433.5M
$363.0M
Q1 25
$-426.2M
$357.9M
Q4 24
$-388.7M
$357.1M
Q3 24
$-370.2M
$352.9M
Q2 24
$-344.2M
$344.9M
Total Assets
ESPR
ESPR
RM
RM
Q1 26
$2.1B
Q4 25
$465.9M
$2.1B
Q3 25
$364.0M
$2.0B
Q2 25
$347.1M
$2.0B
Q1 25
$324.0M
$1.9B
Q4 24
$343.8M
$1.9B
Q3 24
$314.1M
$1.8B
Q2 24
$352.3M
$1.8B
Debt / Equity
ESPR
ESPR
RM
RM
Q1 26
Q4 25
4.40×
Q3 25
4.23×
Q2 25
4.14×
Q1 25
4.11×
Q4 24
4.12×
Q3 24
3.94×
Q2 24
3.98×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ESPR
ESPR
RM
RM
Operating Cash FlowLast quarter
$45.2M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
0.0%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ESPR
ESPR
RM
RM
Q1 26
Q4 25
$45.2M
$309.1M
Q3 25
$-4.3M
$86.7M
Q2 25
$-31.4M
$78.7M
Q1 25
$-22.6M
$63.7M
Q4 24
$-35.0M
$268.9M
Q3 24
$-35.3M
$75.1M
Q2 24
$-7.2M
$71.5M
Free Cash Flow
ESPR
ESPR
RM
RM
Q1 26
Q4 25
$304.3M
Q3 25
$85.7M
Q2 25
$77.6M
Q1 25
$62.4M
Q4 24
$263.9M
Q3 24
$-35.5M
$73.8M
Q2 24
$-7.3M
$70.3M
FCF Margin
ESPR
ESPR
RM
RM
Q1 26
Q4 25
179.3%
Q3 25
51.8%
Q2 25
49.3%
Q1 25
40.8%
Q4 24
170.4%
Q3 24
-68.7%
50.4%
Q2 24
-9.9%
49.1%
Capex Intensity
ESPR
ESPR
RM
RM
Q1 26
Q4 25
0.0%
2.8%
Q3 25
0.0%
0.6%
Q2 25
0.0%
0.6%
Q1 25
0.0%
0.8%
Q4 24
0.0%
3.3%
Q3 24
0.3%
0.9%
Q2 24
0.1%
0.8%
Cash Conversion
ESPR
ESPR
RM
RM
Q1 26
Q4 25
23.94×
Q3 25
6.04×
Q2 25
7.76×
Q1 25
9.09×
Q4 24
27.13×
Q3 24
9.80×
Q2 24
8.47×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ESPR
ESPR

Collaboration Revenue$124.7M74%
Products$43.7M26%

RM
RM

Segment breakdown not available.

Related Comparisons